Alpha-L-Iduronidase (Idua) Newborn Screening Test System
The Alpha-L-Iduronidase (IDUA) Newborn Screening Test System is an in vitro diagnostic device intended for the quantitative measurement of alpha-L-iduronidase enzyme activity from newborn dried blood spot specimens, used as part of newborn screening programs to detect Mucopolysaccharidosis type I (MPS I / Hurler syndrome). It is classified as FDA Class 2 under 21 CFR 862.1488 in the Clinical Chemistry specialty, requiring 510(k) clearance, and is eligible for third-party review. Product code PQT; not an implant and not life-sustaining.
Basic Information
- Product Code
- PQT
- Device Class
- FDA class 2
- Regulation Number
- 862.1488
- Medical Specialty
- Clinical Chemistry
- Review Panel
- CH
- Submission Type
- 1
Device Characteristics
Definition
Intended for quantitative measurement of the activity of alpha-L-iduronidase (IDUA) from newborn dried blood spot specimens.
FEI Numbers
This FDA classification entry is associated with 3 FEI numbers. Click on an entry to view related FDA registrations.
Registration Numbers
This FDA classification entry is associated with 3 registration numbers. Click on an entry to view related FDA registrations.